Search for "phosphate" in Full Text gives 466 result(s) in Beilstein Journal of Organic Chemistry. Showing first 200.
Beilstein J. Org. Chem. 2020, 16, 691–737, doi:10.3762/bjoc.16.67
Graphical Abstract
Scheme 1: Pharmaceuticals possessing a silicon or boron atom.
Scheme 2: The first Cu-catalyzed C(sp3)–Si bond formation.
Scheme 3: Conversion of benzylic phosphate 6 to the corresponding silane.
Scheme 4: Conversion of alkyl triflates to alkylsilanes.
Scheme 5: Conversion of secondary alkyl triflates to alkylsilanes.
Scheme 6: Conversion of alkyl iodides to alkylsilanes.
Scheme 7: Trapping of intermediate radical through cascade reaction.
Scheme 8: Radical pathway for conversion of alkyl iodides to alkylsilanes.
Scheme 9: Conversion of alkyl ester of N-hydroxyphthalimide to alkylsilanes.
Scheme 10: Conversion of gem-dibromides to bis-silylalkanes.
Scheme 11: Conversion of imines to α-silylated amines (A) and the reaction pathway (B).
Scheme 12: Conversion of N-tosylimines to α-silylated amines.
Scheme 13: Screening of diamine ligands.
Scheme 14: Conversion of N-tert-butylsulfonylimines to α-silylated amines.
Scheme 15: Conversion of aldimines to nonracemic α-silylated amines.
Scheme 16: Conversion of N-tosylimines to α-silylated amines.
Scheme 17: Reaction pathway [A] and conversion of aldehydes to α-silylated alcohols [B].
Scheme 18: Conversion of aldehydes to benzhydryl silyl ethers.
Scheme 19: Conversion of ketones to 1,2-diols (A) and conversion of imines to 1,2-amino alcohols (B).
Scheme 20: Ligand screening (A) and conversion of aldehydes to α-silylated alcohols (B).
Scheme 21: Conversion of aldehydes to α-silylated alcohols.
Scheme 22: 1,4-Additions to α,β-unsaturated ketones.
Scheme 23: 1,4-Additions to unsaturated ketones to give β-silylated derivatives.
Scheme 24: Additions onto α,β-unsaturated lactones to give β-silylated lactones.
Scheme 25: Conversion of α,β-unsaturated to β-silylated lactams.
Scheme 26: Conversion of N-arylacrylamides to silylated oxindoles.
Scheme 27: Conversion of α,β-unsaturated carbonyl compounds to silylated tert-butylperoxides.
Scheme 28: Catalytic cycle for Cu(I) catalyzed α,β-unsaturated compounds.
Scheme 29: Conversion of p-quinone methides to benzylic silanes.
Scheme 30: Conversion of α,β-unsaturated ketimines to regio- and stereocontrolled allylic silanes.
Scheme 31: Conversion of α,β-unsaturated ketimines to enantioenriched allylic silanes.
Scheme 32: Regioselective conversion of dienedioates to allylic silanes.
Scheme 33: Conversion of alkenyl-substituted azaarenes to β-silylated adducts.
Scheme 34: Conversion of conjugated benzoxazoles to enantioenriched β-silylated adducts.
Scheme 35: Conversion of α,β-unsaturated carbonyl indoles to α-silylated N-alkylated indoles.
Scheme 36: Conversion of β-amidoacrylates to α-aminosilanes.
Scheme 37: Conversion of α,β-unsaturated ketones to enantioenriched β-silylated ketones, nitriles, and nitro d...
Scheme 38: Regio-divergent silacarboxylation of allenes.
Scheme 39: Silylation of diazocarbonyl compounds, (A) asymmetric and (B) racemic.
Scheme 40: Enantioselective hydrosilylation of alkenes.
Scheme 41: Conversion of 3-acylindoles to indolino-silanes.
Scheme 42: Proposed mechanism for the silylation of 3-acylindoles.
Scheme 43: Silyation of N-chlorosulfonamides.
Scheme 44: Conversion of acyl silanes to α-silyl alcohols.
Scheme 45: Conversion of N-tosylaziridines to β-silylated N-tosylamines.
Scheme 46: Conversion of N-tosylaziridines to silylated N-tosylamines.
Scheme 47: Conversion of 3,3-disubstituted cyclopropenes to silylated cyclopropanes.
Scheme 48: Conversion of conjugated enynes to 1,3-bis(silyl)propenes.
Scheme 49: Proposed sequence for the Cu-catalyzed borylation of substituted alkenes.
Scheme 50: Cu-catalyzed synthesis of nonracemic allylic boronates.
Scheme 51: Cu–NHC catalyzed synthesis of α-substituted allylboronates.
Scheme 52: Synthesis of α-chiral (γ-alkoxyallyl)boronates.
Scheme 53: Cu-mediated formation of nonracemic cis- or trans- 2-substituted cyclopropylboronates.
Scheme 54: Cu-catalyzed synthesis of γ,γ-gem-difluoroallylboronates.
Scheme 55: Cu-catalyzed hydrofunctionalization of internal alkenes and vinylarenes.
Scheme 56: Cu-catalyzed Markovnikov and anti-Markovnikov borylation of alkenes.
Scheme 57: Cu-catalyzed borylation/ortho-cyanation/Cope rearrangement.
Scheme 58: Borylfluoromethylation of alkenes.
Scheme 59: Cu-catalyzed synthesis of tertiary nonracemic alcohols.
Scheme 60: Synthesis of densely functionalized and synthetically versatile 1,2- or 4,3-borocyanated 1,3-butadi...
Scheme 61: Cu-catalyzed trifunctionalization of allenes.
Scheme 62: Cu-catalyzed selective arylborylation of arenes.
Scheme 63: Asymmetric borylative coupling between styrenes and imines.
Scheme 64: Regio-divergent aminoboration of unactivated terminal alkenes.
Scheme 65: Cu-catalyzed 1,4-borylation of α,β-unsaturated ketones.
Scheme 66: Cu-catalyzed protodeboronation of α,β-unsaturated ketones.
Scheme 67: Cu-catalyzed β-borylation of α,β-unsaturated imines.
Scheme 68: Cu-catalyzed synthesis of β-trifluoroborato carbonyl compounds.
Scheme 69: Asymmetric 1,4-borylation of α,β-unsaturated carbonyl compounds.
Scheme 70: Cu-catalyzed ACB and ACA reactions of α,β-unsaturated 2-acyl-N-methylimidazoles.
Scheme 71: Cu-catalyzed diborylation of aldehydes.
Scheme 72: Umpolung pathway for chiral, nonracemic tertiary alcohol synthesis (top) and proposed mechanism for...
Scheme 73: Cu-catalyzed synthesis of α-hydroxyboronates.
Scheme 74: Cu-catalyzed borylation of ketones.
Scheme 75: Cu-catalyzed borylation of unactivated alkyl halides.
Scheme 76: Cu-catalyzed borylation of allylic difluorides.
Scheme 77: Cu-catalyzed borylation of cyclic and acyclic alkyl halides.
Scheme 78: Cu-catalyzed borylation of unactivated alkyl chlorides and bromides.
Scheme 79: Cu-catalyzed decarboxylative borylation of carboxylic acids.
Scheme 80: Cu-catalyzed borylation of benzylic, allylic, and propargylic alcohols.
Beilstein J. Org. Chem. 2020, 16, 451–481, doi:10.3762/bjoc.16.42
Graphical Abstract
Scheme 1: [Cu(I)(dap)2]Cl-catalyzed ATRA reaction under green light irradiation.
Scheme 2: Photocatalytic allylation of α-haloketones.
Scheme 3: [Cu(I)(dap)2]Cl-photocatalyzed chlorosulfonylation and chlorotrifluoromethylation of alkenes.
Scheme 4: Photocatalytic perfluoroalkylchlorination of electron-deficient alkenes using the Sauvage catalyst.
Scheme 5: Photocatalytic synthesis of fluorinated sultones.
Scheme 6: Photocatalyzed haloperfluoroalkylation of alkenes and alkynes.
Scheme 7: Chlorosulfonylation of alkenes catalyzed by [Cu(I)(dap)2]Cl. aNo Na2CO3 was added. b1 equiv of Na2CO...
Scheme 8: Copper-photocatalyzed reductive allylation of diaryliodonium salts.
Scheme 9: Copper-photocatalyzed azidomethoxylation of olefins.
Scheme 10: Benzylic azidation initiated by [Cu(I)(dap)2]Cl.
Scheme 11: Trifluoromethyl methoxylation of styryl derivatives using [Cu(I)(dap)2]PF6. All redox potentials ar...
Scheme 12: Trifluoromethylation of silyl enol ethers.
Scheme 13: Synthesis of annulated heterocycles upon oxidation with the Sauvage catalyst.
Scheme 14: Oxoazidation of styrene derivatives using [Cu(dap)2]Cl as a precatalyst.
Scheme 15: [Cu(I)(dpp)(binc)]PF6-catalyzed ATRA reaction.
Scheme 16: Allylation reaction of α-bromomalonate catalyzed by [Cu(I)(dpp)(binc)]PF6 following an ATRA mechani...
Scheme 17: Bromo/tribromomethylation reaction using [Cu(I)(dmp)(BINAP)]PF6.
Scheme 18: Chlorotrifluoromethylation of alkenes catalyzed by [Cu(I)(N^N)(xantphos)]PF6.
Scheme 19: Chlorosulfonylation of styrene and alkyne derivatives by ATRA reactions.
Scheme 20: Reduction of aryl and alkyl halides with the complex [Cu(I)(bcp)(DPEPhos)]PF6. aIrradiation was car...
Scheme 21: Meerwein arylation of electron-rich aromatic derivatives and 5-exo-trig cyclization catalyzed by th...
Scheme 22: [Cu(I)(bcp)(DPEPhos)]PF6-photocatalyzed synthesis of alkaloids. aYield over two steps (cyclization ...
Scheme 23: Copper-photocatalyzed decarboxylative amination of NHP esters.
Scheme 24: Photocatalytic decarboxylative alkynylation using [Cu(I)(dq)(binap)]BF4.
Scheme 25: Copper-photocatalyzed alkylation of glycine esters.
Scheme 26: Copper-photocatalyzed borylation of organic halides. aUnder continuous flow conditions.
Scheme 27: Copper-photocatalyzed α-functionalization of alcohols with glycine ester derivatives.
Scheme 28: δ-Functionalization of alcohols using [Cu(I)(dmp)(xantphos)]BF4.
Scheme 29: Photocatalytic synthesis of [5]helicene and phenanthrene.
Scheme 30: Oxidative carbazole synthesis using in situ-formed [Cu(I)(dmp)(xantphos)]BF4.
Scheme 31: Copper-photocatalyzed functionalization of N-aryl tetrahydroisoquinolines.
Scheme 32: Bicyclic lactone synthesis using a copper-photocatalyzed PCET reaction.
Scheme 33: Photocatalytic Pinacol coupling reaction catalyzed by [Cu(I)(pypzs)(BINAP)]BF4. The ligands of the ...
Scheme 34: Azide photosensitization using a Cu-based photocatalyst.
Beilstein J. Org. Chem. 2020, 16, 351–361, doi:10.3762/bjoc.16.34
Graphical Abstract
Scheme 1: [HSO3-BDBU]H2PO4-promoted oligomerization and separation.
Scheme 2: Structures of ILs used in this work.
Figure 1: Monitoring oligomerization process by 1H NMR (400 MHz, CDCl3).
Figure 2: Reusability of the IL catalyst. Reaction conditions: 10 g (30 mmol) ricinoleic acid, 190 °C, 6 h, 5...
Figure 3: 1H NMR (400 MHz, DMSO-d6) spectra of [HSO3-BDBU]H2PO4: a) Fresh one; b) used one after five cycles.
Scheme 3: Proposed mechanism for [HSO3-BDBU]H2PO4 catalyzed oligomeric ricinoleic acid synthesis.
Beilstein J. Org. Chem. 2020, 16, 125–134, doi:10.3762/bjoc.16.14
Graphical Abstract
Figure 1: a) The potent tubulin inhibitor colchicine as a lead scaffold led to the development of the HOTub g...
Figure 2: Chemical structures of HITubs. Key variations with respect to HITub-4 are highlighted in dashed box...
Figure 3: Photocharacterisation of HITub-4. a) Photochemical and thermal isomerisation. b) UV–vis spectra aft...
Figure 4: a) Resazurin reduction assay for HITub-4 and nocodazole in HeLa cells (n = 3), demonstrating the di...
Figure 5: Confocal microscopy images of immunofluorescently labelled MT networks after treatment with HITubs ...
Figure 6: Cell cycle analysis of HITub-4-treated cells. a) and b) (Z)-HITub-4 caused significant G2/M arrest ...
Beilstein J. Org. Chem. 2020, 16, 111–124, doi:10.3762/bjoc.16.13
Graphical Abstract
Scheme 1: Synthesis of styrylquinolizinium derivatives 3a–d.
Figure 1: Absorption spectra and normalized emission spectrum (Abs. = 0.10, 3b: λex = 394 nm) of derivatives ...
Figure 2: Spectrophotometric titration upon the addition of ct DNA to the styrylquinolizinium derivatives 3a ...
Figure 3: Spectrofluorimetric titration upon the addition of ct DNA to the styrylquinolizinium derivatives 3a...
Figure 4: CD and LD spectra of the styryl derivatives 3a (A), 3b (B), 3c (C), and 3d (D) with ct DNA in BPE b...
Figure 5: Spectrophotometric monitoring of the irradiation of styrylquinolizinium derivatives 3a (A), 3b (B), ...
Figure 6: Absorption of the monomers (c = 20 µM, red) 3b (A) and 3c (B) and their dimers (black) 4b and 4c in...
Figure 7: Photometric monitoring of the photoreaction of 3b (c = 20 µM) to the dimer 4b by irradiation at ca....
Figure 8: ORTEP drawings of cyclobutane derivatives 4b (A) and 4c (B) in the solid state (thermal ellipsoids ...
Scheme 2: Possible pathways for the selective photodimerization of styrylquinolizinium derivatives 3b and 3c.
Figure 9: A) Spectrophotometric titration of ct DNA to dimer 4b in BPE buffer (cL = 20 µM, cct DNA = 1.45 mM, ...
Figure 10: A) Photometric and B) CD spectroscopic monitoring of the photoinduced switching (4b: λex = 315 nm, ...
Scheme 3: Photoinduced switching of the DNA binding properties of styrylquinolizinium compound 3b.
Beilstein J. Org. Chem. 2020, 16, 71–77, doi:10.3762/bjoc.16.9
Graphical Abstract
Figure 1: Chemical structures of baicalein (left), cucurbit[8]uril (right).
Figure 2: The possible interaction model for Q[8] and baicalein.
Figure 3: 1H NMR spectra (400 MHz) of Q[8] (a), baicalein (b) and BALE–Q[8] (1:1) (c) recorded in DCl.
Figure 4: The absorption spectra of BALE upon the addition of Q[8] under different conditions [10 mol·L−1 HCl...
Figure 5: IR spectra of Q[8] (a), BALE (b), a physical mixture of Q[8]-BALE (NQ[8]/NBALE = 1:1) (c) and the B...
Figure 6: DTA spectra of BALE (a), Q[8] (b), a physical mixture Q[8]-BALE (NQ[8]/NBALE = 1:1) (c) and the BAL...
Figure 7: The stability curve of UV–vis absorption obtained for an isoconcentration of BALE and the BALE–Q[8]...
Figure 8: The phase solubility graph obtained for BALE in Q[8] at λ = 270 nm.
Figure 9: The clearance rate curve (A) and clearance time curve (B) of ABTS+· upon increasing the concentrati...
Figure 10: The release curves of BALE and BALE–Q[8].
Beilstein J. Org. Chem. 2020, 16, 9–14, doi:10.3762/bjoc.16.2
Graphical Abstract
Figure 1: Modification of lipid A by ArnT.
Scheme 1: Phosphonate and glycal synthesis.
Scheme 2: Synthesis of methyl phosphonate 11 and octyl phosphonates 16 and 17.
Beilstein J. Org. Chem. 2019, 15, 3000–3008, doi:10.3762/bjoc.15.296
Graphical Abstract
Figure 1: Structures of azonium ions studied.
Figure 2: a) Structures of model compounds used for computations (see Experimental section; in calculations, ...
Scheme 1: Synthesis of bis(4-amino-2-bromo-6-methoxy)azobenzene compounds.
Figure 3: a) UV–vis spectra of 4 in DCM (ca. 15 µM) at the PSS and 440 nm irradiation (thick dotted line; ca....
Figure 4: a) UV–vis spectra of 5 in aqueous solution (c ≈ 15 µM, 5% methanol, pH 7) at the PSS and 440 nm irr...
Beilstein J. Org. Chem. 2019, 15, 2889–2906, doi:10.3762/bjoc.15.283
Graphical Abstract
Figure 1: Examples of bioactive terpenoids.
Figure 2: Repetitive electrophilic and nucleophilic functionalities in terpene and type II PKS-derived polyke...
Figure 3: Abundance and distribution of bacterial terpene biosynthetic gene clusters as determined by genome ...
Figure 4: Terpenoid biosynthesis. Terpenoid biosynthesis is divided into two phases, 1) terpene scaffold gene...
Figure 5: Mechanisms for type I, type II, and type II/type I tandem terpene cyclases. a) Tail-to-head class I...
Figure 6: Functional TC characterization. a) Different terpenes were produced when hedycaryol (18) synthase a...
Figure 7: Selected examples of terpene modification by bacterial CYPs. a) Hydroxylation [89]. b) Carboxylation, h...
Figure 8: Off-target effects observed during heterologous expression of terpenoid BGCs. Unexpected oxidation ...
Figure 9: TC promiscuity and engineering. a) Spata-13,17-diene (39) synthase (SpS) can take C15 and C25 oligo...
Figure 10: Substrate promiscuity and engineering of CYPs. a) Selected examples from using a CYP library to oxi...
Figure 11: Engineering of terpenoid pathways. a) Metabolic network of terpenoid biosynthesis. Toxic intermedia...
Beilstein J. Org. Chem. 2019, 15, 2872–2880, doi:10.3762/bjoc.15.281
Graphical Abstract
Figure 1: Plasmodia of P. polycephalum emit a mixture of volatiles predominated by terpenoids. A) GC chromato...
Figure 2: P. polycephalum contains four terpene synthase genes. A) Multiple sequence alignment of the protein...
Figure 3: PpolyTPS1 and PpolyTPS4 have terpene synthase activities. A) GC chromatogram of sesquiterpenes prod...
Figure 4: Phylogenetic analysis of PpolyTPSs with TPSs from dictyostelid social amoebae (Dictyostelids), the ...
Beilstein J. Org. Chem. 2019, 15, 2830–2839, doi:10.3762/bjoc.15.276
Graphical Abstract
Figure 1: Pharmacologically relevant furoindoles.
Scheme 1: Synthesis of benzo[4,5]furo[3,2-b]indoles 5a–j. Conditions: (i) 1.2 equiv 2-bromophenylboronic acid...
Figure 2: Ortep of 5c (propability of ellipsoids: 45%).
Figure 3: Diindolofurans 6a–e.
Figure 4: Illustration of binding poses of selected inhibitors for the ENPP1 homology model: (a): suramin, (b...
Figure 5: 3D poses of docked selected inhibitors inside homology model of ENPP3. (a): suramin, (b): 5e, (c): ...
Beilstein J. Org. Chem. 2019, 15, 2822–2829, doi:10.3762/bjoc.15.275
Graphical Abstract
Scheme 1: Synthesis of hemi-indigo derivatives Z-1a–c.
Scheme 2: Synthetic routes to alkylamino-substituted dimethoxy hemi-indigo Z-1c.
Figure 1: Photoswitching of hemi-indigo derivatives: (A) Z-1a, c = 20 μM in H2O with 10% (v/v) DMSO, λex = 42...
Scheme 3: Photoswitching of hemi-indigo derivatives.
Figure 2: Absorption spectra of the Z-isomer (black), two photostationary states obtained upon irradiation wi...
Beilstein J. Org. Chem. 2019, 15, 2782–2789, doi:10.3762/bjoc.15.270
Graphical Abstract
Figure 1: HPLC–UV chromatogram of the extract from fruiting bodies of Skeletocutis sp. (detection wavelength ...
Figure 2: Chemical structures of compounds 1–6.
Figure 3: Inhibition Leu-AMC hydrolysis. a) c (ʟ-Leu-AMC) = 100 µM. b) c (ʟ-Leu-AMC) = 50 µM.
Beilstein J. Org. Chem. 2019, 15, 2774–2781, doi:10.3762/bjoc.15.269
Graphical Abstract
Scheme 1: Conventional method of synthesis of thiazolidine-2,4-dione derivatives.
Scheme 2: [2 + 2 + 2] Cyclotrimerization of N-methylthiazolidinedione.
Scheme 3: Unexpected product 5b obtained in the attempted NH-protection of thiazolidinedione with (Boc)2O.
Figure 1: Comparison of 13C NMR values of 9 and 5b.
Scheme 4: [2 + 2 + 2] Cyclotrimerization of dipropargylthiazolidinediones with propargyl halides.
Scheme 5: Formation of sultine 13 from compound 8b followed by DA reaction.
Scheme 6: Dipropargylation of 2,4-thiazolidinedione derivatives.
Scheme 7: [2 + 2 + 2] Cycloaddition in the presence of Wilkinson’s catalyst.
Scheme 8: N-Ester derivative 18 hydrolysis to N-acid derivative 22.
Scheme 9: Synthesis of triazolo derivative 24 via click reaction.
Beilstein J. Org. Chem. 2019, 15, 2577–2589, doi:10.3762/bjoc.15.251
Graphical Abstract
Scheme 1: Handling of azide chemistry in Tamiflu synthesis by Hayashi and co-workers [14].
Figure 1: Synthesis of compound 2 from acyl chloride 1 via Curtius rearrangement using a continuous-flow syst...
Scheme 2: Azide chemistry in the synthesis of Tamiflu.
Scheme 3: Azidation of mesyl shikimate 5.
Figure 2: Continuous-flow system for C-3 azidation of mesyl shikimate using aqueous sodium azide.
Figure 3: Mesyl shikimate azidation conversion in a continuous-flow system using NaN3.
Figure 4: Desired azide 5 selectivity in a continuous-flow system using NaN3.
Figure 5: Effect of NaN3 concentration on mesyl shikimate 4 conversion and azide 5 selectivity.
Figure 6: Regio- and stereospecific nucleophilic -N3 group attack.
Figure 7: Continuous-flow system for C-3 azidation of mesyl shikimate using DPPA or TMSA.
Figure 8: Mesyl shikimate azidation conversion in a continuous-flow system using DPPA.
Figure 9: Desired azide 5 selectivity in a continuous-flow system using DPPA.
Scheme 4: DPPA azidating mechanism in the presence of a base.
Figure 10: Effect of TEA concentration on the reaction selectivity.
Figure 11: Mesyl shikimate azidation conversion in a continuous-flow system using TMSA.
Figure 12: Desired azide 5 selectivity in a continuous-flow system using TMSA.
Figure 13: Continuous-flow system for C-3 azidation of mesyl shikimate using TBAA.
Figure 14: Continuous-flow system for C-3 azidation of mesyl shikimate using TBAA.
Scheme 5: C-5 azidation of acetamide 6 in our proposed route.
Figure 15: Continuous flow system for C-5 azidation of acetamide 6 using NaN3.
Figure 16: Continuous-flow C-5 azidation of acetamide 6 using NaN3.
Figure 17: Continuous flow C-5 azidation of acetamide 6 using various azidating agents.
Figure 18: Continuous flow synthesis of azide 7 from acetamide 6 using various azidating agents.
Beilstein J. Org. Chem. 2019, 15, 2524–2533, doi:10.3762/bjoc.15.245
Graphical Abstract
Figure 1: Some hydroxamic acid-based anti-tumor drugs.
Scheme 1: Synthesis of SAHA and DDSAHA.
Figure 2: Cell viability from MTT assay for SAHA, 11b, 11f and 11g on HeLa after 24 h treatment.
Figure 3: Percent of cell death by LDH assay at a GI50 dose of SAHA, 11b, 11f and 11g after 24 h incubation a...
Figure 4: ROS generation by DCFDA.
Figure 5: The quantitative results of bivariate FITC-Annexin V/PI FCM of HeLa cells after treatment with 11b ...
Figure 6: Fluorescence microscopic images of 11b at different concentrations (8.9, and 14.2 µM, respectively)...
Figure 7: DNA Ladder formation in a gel electrophoresis study of 11b at different concentrations (at 8.9, and...
Beilstein J. Org. Chem. 2019, 15, 2500–2508, doi:10.3762/bjoc.15.243
Graphical Abstract
Figure 1: A) Structure of the pioneering azobenzene-modified DNA [16] compared with the photoswitchable PNA struc...
Scheme 1: Solid-phase synthesis of photoswitchable PNAs; Aeg = N-(2-aminoethyl)glycine, Bhoc = benzhydryloxyc...
Figure 2: Time-dependent conversion to the thermodynamically stable isomer of PNA12(oF4Azo) (3; green triangl...
Figure 3: A) Melting curves of a 1 µM duplex solution in phosphate buffer (10 mM NaH2PO4, 150 mM NaCl, pH 7.4...
Figure 4: Outline of the displacement assay principle, in which a photoswitchable PNA probe (blue) hybridizes...
Figure 5: Time-dependent fluorescence signals from two independent experiments at 520 nm of 0.75 μM FAM/BHQ-d...
Beilstein J. Org. Chem. 2019, 15, 2277–2286, doi:10.3762/bjoc.15.220
Graphical Abstract
Figure 1: Structures of target compounds 1 and reference compound Ph1b.
Figure 2: Cyclic voltammograms (left) and differential pulse voltammograms (right) of (top) 1a, (middle) Ph1b,...
Figure 3: Key frontier orbitals (isosurface values 0.02 au) (top), DFT-optimized structures with Mullliken ch...
Figure 4: UV–vis-NIR spectral changes of CH2Cl2/n-Bu4NPF6 (0.10 M) solutions containing (a) 1b (4.5 × 10−4 M)...
Figure 5: Vis-NIR spectra of 1b+ (green line) obtained by bulk electrolysis, with Gaussian deconvolutions (bl...
Beilstein J. Org. Chem. 2019, 15, 2142–2155, doi:10.3762/bjoc.15.211
Graphical Abstract
Figure 1: Hydrogen, halogen or chalcogen bonding to anions within a bistriazolium macrocycle.
Figure 2: Main synthetic strategies towards macrocyclic triazoliums.
Figure 3: Chemical structure of compound 1 (1a, 1b and 1c) and 2.
Figure 4: Chemical structure of compound 3 and 4.
Figure 5: Chemical structure of compound 5.
Figure 6: Chemical structure of compound 6.
Figure 7: Chemical structure of compound 7.
Figure 8: Chemical structure of compound 8.
Figure 9: Chemical structures of compound 9.
Figure 10: Chemical structures of compound 10, 11 and 12.
Figure 11: Chemical structure of compound 13.
Figure 12: Chemical structure of compound 15 including the sigma-connected TCNQ dimer.
Figure 13: Chemical structure of compound 16 for the kinetic resolution of epoxides.
Figure 14: Chemical structure of compound 17a (bisnaphtho crown ether shown).
Figure 15: Jump rope in molecular double-lasso compounds 18.
Figure 16: Chemical structure of compound 19 and acid–base triggered motions.
Beilstein J. Org. Chem. 2019, 15, 2076–2084, doi:10.3762/bjoc.15.205
Graphical Abstract
Scheme 1: Asymmetric α-photooxygenation of chiral aldehydes.
Scheme 2: α-Photooxygenation of β-substituted aldehydes.
Scheme 3: Synthesis and α-photooxygenation of 3,4-diphenylbutanal (1).
Scheme 4: Stereoselective α-photooxygenation of 3,4-diphenylbutanal (1) with 1O2.
Scheme 5: Schematic representation of the in situ methodology and preferred conformation of diols with Mo2 co...
Figure 1: ECD spectra of diols syn-6 and anti’-6 recorded a) with 19 in DMSO and b) in acetonitrile compared ...
Scheme 6: Asymmetric synthesis of 3,4-diphenylbutane-1,2-diol.
Beilstein J. Org. Chem. 2019, 15, 2036–2042, doi:10.3762/bjoc.15.200
Graphical Abstract
Figure 1: Structure of nitroxide 1.
Scheme 1: The synthesis of aldonitrones 5a–c.
Scheme 2: The principal synthetic scheme for nitroxides 12a–c.
Scheme 3: A possible pathway of ketonitrone 7c self-transformations.
Scheme 4: Oxidation of aminoalcohol 9a.
Scheme 5: The synthesis of alkoxyamines 16a–c.
Scheme 6: The alkoxyamine 18 synthesis.
Scheme 7: A possible mechanism of nitroxide 17 formation.
Scheme 8: Optimisation of the synthesis of nitroxide 1.
Figure 2: Kinetics of the reduction of nitroxides 1 and 12a–c (0.3 mM) with ascorbate (50 mM) in 50 mM phosph...
Beilstein J. Org. Chem. 2019, 15, 1945–1961, doi:10.3762/bjoc.15.190
Graphical Abstract
Figure 1: Contour plot of a HS-SPME–GC×GC–TOF–MS chromatogram (TIC) demonstrating the separation of volatile ...
Figure 2: Sesquiterpene hydrocarbons found in the headspace of Lemberger (Vitis vinifera subsp. vinifera, clo...
Figure 3: Detailed part of the two-dimensional contour plot (Figure 1) to demonstrate the result of a successful feed...
Scheme 1: First steps towards the formation of sesquiterpenes. The (S)-germacradienyl cation can be formed fr...
Scheme 2: Possible biosynthetic pathways of the sesquiterpene hydrocarbons d8-α-copaene, d8-β-copaene, d8-α-c...
Scheme 3: Mechanistic rationale for the generation of the sesquiterpene hydrocarbons δ-cadinene (14), α-copae...
Figure 4: MS spectra of genuine (d0) and deuterium-labeled (d6 and d8) α-cubebene (left panel) after administ...
Scheme 4: Putative formation pathways of the sesquiterpene hydrocarbons α-ylangene (5), β-ylangene (6), β-bou...
Figure 5: MS spectra and expected labeling patterns of A: d0-α-ylangene, B: d8-α-ylangene after administratio...
Figure 6: Expected labeling patterns of deuterium-labeled, aromatic sesquiterpenes after administration of [6...
Figure 7: MS spectra and expected labeling patterns of genuine and deuterium-labeled A: calamenene (isomer) a...
Figure 8: MS spectra and expected labeling patterns of genuine (d0) and deuterium-labeled (d9) β-elemene afte...
Scheme 5: Possible biosynthesis of d9-β-elemene, d9-(+)-valencene and d9-α-guaiene via germacrene A. *An inco...
Scheme 6: Mechanistic rationale for the generation of the sesquiterpene hydrocarbons γ-elemene and selina-3,7...
Figure 9: Mass spectra and associated structural formulas of d0-γ-elemene and d9-γ-elemene after administrati...
Figure 10: MS spectra and expected labeling patterns of genuine (d0) and deuterium-labeled (d9) guaiazulene af...
Scheme 7: Possible synthesis of d9-guaiazulene, d9-δ-elemene, d9-guaia-6,9-diene and d9-δ-selinene via germac...
Scheme 8: Possible biosynthesis of d6-(E)-β-caryophyllene and d5-α-humulene starting from farnesyl pyrophosph...
Figure 11: MS spectra and expected labeling patterns of d0-(E)-β-caryophyllene and d6-(E)-β-caryophyllene afte...
Beilstein J. Org. Chem. 2019, 15, 1933–1944, doi:10.3762/bjoc.15.189
Graphical Abstract
Figure 1: The structure of the sesquiterpene lactones archangelolide (1) and trilobolide (2).
Scheme 1: Reagents and conditions: a) MeOH, TEA, 48 h, yield 32%; b) (i) 5-azidopentanoic acid, DCC, DCM, 90 ...
Figure 2: Intracellular localization of archangelolide-dansyl (5) in human cells from osteosarcoma (U-2 OS). ...
Figure 3: Co-localization of dansylarchangelolide 5 with a marker of endoplasmic reticulum (top row) and with...
Figure 4: Cartoon representation of sarco/endoplasmic reticulum Ca2+ ATPase binding pocket with A, C) archang...
Figure 5: Molecular surface representation of sarco/endoplasmic reticulum Ca2+ ATPase binding pocket with A) ...
Figure 6: Structural formulae of (i) thapsigargin, (ii) trilobolide (2), and (iii) archangelolide (1). Red pa...
Figure 7: Viability of rat peritoneal cells treated with archangelolide (1), dansylarchangelolide 5 and dansy...
Figure 8: NO production in primary rat macrophages. The cells were treated with archangelolide (1) and dansyl...
Figure 9: Evaluation of cytokine TNF-α secretion in rat peritoneal cells. Stimulation of primary cells was in...
Figure 10: Structure of laserolide.
Beilstein J. Org. Chem. 2019, 15, 1722–1757, doi:10.3762/bjoc.15.168
Graphical Abstract
Figure 1: Examples of three-carbon chirons.
Figure 2: Structures of derivatives of N-(1-phenylethyl)aziridine-2-carboxylic acid 5–8.
Figure 3: Synthetic equivalency of aziridine aldehydes 6.
Scheme 1: Synthesis of N-(1-phenylethyl)aziridine-2-carboxylates 5. Reagents and conditions: a) TEA, toluene,...
Scheme 2: Absolute configuration at C2 in (2S,1'S)-5a. Reagents and conditions: a) 20% HClO4, 80 °C, 30 h the...
Scheme 3: Major synthetic strategies for a 2-ketoaziridine scaffold [R* = (R)- or (S)-1-phenylethyl; R′ = Alk...
Scheme 4: Synthesis of cyanide (2S,1'S)-13. Reagents and conditions: a) NH3, EtOH/H2O, rt, 72 h; b) Ph3P, CCl4...
Scheme 5: Synthesis of key intermediates (R)-16 and (R)-17 for (R,R)-formoterol (14) and (R)-tamsulosin (15)....
Scheme 6: Synthesis of mitotic kinesin inhibitors (2R/S,1'R)-23. Reagents and conditions: a) H2, Pd(OH)2, EtO...
Scheme 7: Synthesis of (R)-mexiletine ((R)-24). Reagents and conditions: a) TsCl, TEA, DMAP, CH2Cl2, rt, 1 h;...
Scheme 8: Synthesis of (−)-cathinone ((S)-27). Reagents and conditions: a) PhMgBr, ether, 0 °C; b) H2, 10% Pd...
Scheme 9: Synthesis of N-Boc-norpseudoephedrine ((1S,2S)-(+)-29) and N-Boc-norephedrine ((1R,2S)-29). Reagent...
Scheme 10: Synthesis of (−)-ephedrine ((1R,2S)-31). Reagents and conditions: a) TfOMe, MeCN then NaBH3CN, rt; ...
Scheme 11: Synthesis of xestoaminol C ((2S,3R)-35), 3-epi-xestoaminol C ((2S,3S)-35) and N-Boc-spisulosine ((2S...
Scheme 12: Synthesis of ʟ-tryptophanol ((S)-41). Reagents and conditions: a) CDI, MeCN, rt, 1 h then TMSI, MeC...
Scheme 13: Synthesis of ʟ-homophenylalaninol ((S)-42). Reagents and conditions: a) NaH, THF, 0 °C to −78 °C, 1...
Scheme 14: Synthesis of ᴅ-homo(4-octylphenyl)alaninol ((R)-47) and a sphingolipid analogue (R)-48. Reagents an...
Scheme 15: Synthesis of florfenicol ((1R,2S)-49). Reagents and conditions: a) (S)-1-phenylethylamine, TEA, MeO...
Scheme 16: Synthesis of natural tyroscherin ((2S,3R,6E,8R,10R)-55). Reagents and conditions: a) I(CH2)3OTIPS, t...
Scheme 17: Syntheses of (−)-hygrine (S)-61, (−)-hygroline (2S,2'S)-62 and (−)-pseudohygroline (2S,2'R)-62. Rea...
Scheme 18: Synthesis of pyrrolidine (3S,3'R)-68, a fragment of the fluoroquinolone antibiotic PF-00951966. Rea...
Scheme 19: Synthesis of sphingolipid analogues (R)-76. Reagents and conditions: a) BnBr, Mg, THF, reflux, 6 h;...
Scheme 20: Synthesis of ᴅ-threo-PDMP (1R,2R)-81. Reagents and conditions: a) TMSCl, NaI, MeCN, rt, 1 h 50 min,...
Scheme 21: Synthesis of the sphingolipid analogue SG-14 (2S,3S)-84. Reagents and conditions: a) LiAlH4, THF, 0...
Scheme 22: Synthesis of the sphingolipid analogue SG-12 (2S,3R)-88. Reagents and conditions: a) 1-(bromomethyl...
Scheme 23: Synthesis of sphingosine-1-phosphate analogues DS-SG-44 and DS-SG-45 (2S,3R)-89a and (2S,3R)-89a. R...
Scheme 24: Synthesis of N-Boc-safingol ((2S,3S)-95) and N-Boc-ᴅ-erythro-sphinganine ((2S,3R)-95). Reagents and...
Scheme 25: Synthesis of ceramide analogues (2S,3R)-96. Reagents and conditions: a) NaBH4, ZnCl2, MeOH, −78 °C,...
Scheme 26: Synthesis of orthogonally protected serinols, (S)-101 and (R)-102. Reagents and conditions: a) BnBr...
Scheme 27: Synthesis of N-acetyl-3-phenylserinol ((1R,2R)-105). Reagents and conditions: a) AcOH, CH2Cl2, refl...
Scheme 28: Synthesis of (S)-linezolid (S)-107. Reagents and conditions: a) LiAlH4, THF, 0 °C to reflux; b) Boc2...
Scheme 29: Synthesis of (2S,3S,4R)-2-aminooctadecane-1,3,4-triol (ᴅ-ribo-phytosphingosine) (2S,3S,4R)-110. Rea...
Scheme 30: Syntheses of ᴅ-phenylalanine (R)-116. Reagents and conditions: a) AcOH, CH2Cl2, reflux, 4 h; b) MsC...
Scheme 31: Synthesis of N-Boc-ᴅ-3,3-diphenylalanine ((R)-122). Reagents and conditions: a) PhMgBr, THF, −78 °C...
Scheme 32: Synthesis of ethyl N,N’-di-Boc-ʟ-2,3-diaminopropanoate ((S)-125). Reagents and conditions: a) NaN3,...
Scheme 33: Synthesis of the bicyclic amino acid (S)-(+)-127. Reagents and conditions: a) BF3·OEt2, THF, 60 °C,...
Scheme 34: Synthesis of lacosamide, (R)-2-acetamido-N-benzyl-3-methoxypropanamide (R)-130. Reagents and condit...
Scheme 35: Synthesis of N-Boc-norfuranomycin ((2S,2'R)-133). Reagents and conditions: a) H2C=CHCH2I, NaH, THF,...
Scheme 36: Synthesis of MeBmt (2S,3R,4R,6E)-139. Reagents and conditions: a) diisopropyl (S,S)-tartrate (E)-cr...
Scheme 37: Synthesis of (+)-polyoxamic acid (2S,3S,4S)-144. Reagents and conditions: a) AD-mix-α, MeSO2NH2, t-...
Scheme 38: Synthesis of the protected 3-hydroxy-ʟ-glutamic acid (2S,3R)-148. Reagents and conditions: a) LiHMD...
Scheme 39: Synthesis of (+)-isoserine (R)-152. Reagents and conditions: a) AcCl, MeCN, rt, 0.5 h then Na2CO3, ...
Scheme 40: Synthesis of (3R,4S)-N3-Boc-3,4-diaminopentanoic acid (3R,4S)-155. Reagents and conditions: a) Ph3P...
Scheme 41: Synthesis of methyl (2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoate (2S,3S,4S)-159. ...
Scheme 42: Syntheses of methyl (3S,4S) 4,5-di-N-Boc-amino-3-hydroxypentanoate ((3S,4S)-164), methyl (3S,4S)-4-N...
Scheme 43: Syntheses of (3R,5S)-5-(aminomethyl)-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one ((3R,5S)-168). Reage...
Scheme 44: Syntheses of a series of imidazolin-2-one dipeptides 175–177 (for R' and R'' see text). Reagents an...
Scheme 45: Syntheses of (2S,3S)-N-Boc-3-hydroxy-2-hydroxymethylpyrrolidine ((2S,3S)-179). Reagents and conditi...
Scheme 46: Syntheses of enantiomers of 1,4-dideoxy-1,4-imino-ʟ- and -ᴅ-lyxitols (2S,3R,4S)-182 and (2R,3S,4R)-...
Scheme 47: Synthesis of 1,4-dideoxy-1,4-imino-ʟ-ribitol (2S,3S,4R)-182. Reagents and conditions: a) AcOH, CH2Cl...
Scheme 48: Syntheses of 1,4-dideoxy-1,4-imino-ᴅ-arabinitol (2R,3R,4R)-182 and 1,4-dideoxy-1,4-imino-ᴅ-xylitol ...
Scheme 49: Syntheses of natural 2,5-imino-2,5,6-trideoxy-ʟ-gulo-heptitol ((2S,3R,4R,5R)-184) and its C4 epimer...
Scheme 50: Syntheses of (−)-dihydropinidine ((2S,6R)-187a) (R = C3H7) and (2S,6R)-isosolenopsins (2S,6R)-187b ...
Scheme 51: Syntheses of (+)-deoxocassine ((2S,3S,6R)-190a, R = C12H25) and (+)-spectaline ((2S,3S,6R)-190b, R ...
Scheme 52: Synthesis of (−)-microgrewiapine A ((2S,3R,6S)-194a) and (+)-microcosamine A ((2S,3R,6S)-194b). Rea...
Scheme 53: Syntheses of ʟ-1-deoxynojirimycin ((2S,3S,4S,5R)-200), ʟ-1-deoxymannojirimycin ((2S,3S,4S,5S)-200) ...
Scheme 54: Syntheses of 1-deoxy-ᴅ-galacto-homonojirimycin (2R,3S,4R,5S)-211. Reagents and conditions: a) MeONH...
Scheme 55: Syntheses of 7a-epi-hyacinthacine A1 (1S,2R,3R,7aS)-220. Reagents and conditions: a) TfOTBDMS, 2,6-...
Scheme 56: Syntheses of 8-deoxyhyacinthacine A1 ((1S,2R,3R,7aR)-221). Reagents and conditions: a) H2, Pd/C, PT...
Scheme 57: Syntheses of (+)-lentiginosine ((1S,2S,8aS)-227). Reagents and conditions: a) (EtO)2P(O)CH2COOEt, L...
Scheme 58: Syntheses of 8-epi-swainsonine (1S,2R,8S,8aR)-231. Reagents and conditions: a) Ph3P=CHCOOMe, MeOH, ...
Scheme 59: Synthesis of a protected vinylpiperidine (2S,3R)-237, a key intermediate in the synthesis of (−)-sw...
Scheme 60: Synthesis of a modified carbapenem 245. Reagents and conditions: a) AcOEt, LiHMDS, THF, −78 °C, 1.5...
Beilstein J. Org. Chem. 2019, 15, 1612–1704, doi:10.3762/bjoc.15.165
Graphical Abstract
Figure 1: Various drugs having IP nucleus.
Figure 2: Participation percentage of various TMs for the syntheses of IPs.
Scheme 1: CuI–NaHSO4·SiO2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 2: Experimental examination of reaction conditions.
Scheme 3: One-pot tandem reaction for the synthesis of 2-haloimidazopyridines.
Scheme 4: Mechanistic scheme for the synthesis of 2-haloimidazopyridine.
Scheme 5: Copper-MOF-catalyzed three-component reaction (3-CR) for imidazo[1,2-a]pyridines.
Scheme 6: Mechanism for copper-MOF-driven synthesis.
Scheme 7: Heterogeneous synthesis via titania-supported CuCl2.
Scheme 8: Mechanism involving oxidative C–H functionalization.
Scheme 9: Heterogeneous synthesis of IPs.
Scheme 10: One-pot regiospecific synthesis of imidazo[1,2-a]pyridines.
Scheme 11: Vinyl azide as an unprecedented substrate for imidazo[1,2-a]pyridines.
Scheme 12: Radical pathway.
Scheme 13: Cu(I)-catalyzed transannulation approach for imidazo[1,5-a]pyridines.
Scheme 14: Plausible radical pathway for the synthesis of imidazo[1,5-a]pyridines.
Scheme 15: A solvent-free domino reaction for imidazo[1,2-a]pyridines.
Scheme 16: Cu-NPs-mediated synthesis of imidazo[1,2-a]pyridines.
Scheme 17: CuI-catalyzed synthesis of isoxazolylimidazo[1,2-a]pyridines.
Scheme 18: Functionalization of 4-bromo derivative via Sonogashira coupling reaction.
Scheme 19: A plausible reaction pathway.
Scheme 20: Cu(I)-catalyzed intramolecular oxidative C–H amidation reaction.
Scheme 21: One-pot synthetic reaction for imidazo[1,2-a]pyridine.
Scheme 22: Plausible reaction mechanism.
Scheme 23: Cu(OAc)2-promoted synthesis of imidazo[1,2-a]pyridines.
Scheme 24: Mechanism for aminomethylation/cycloisomerization of propiolates with imines.
Scheme 25: Three-component synthesis of imidazo[1,2-a]pyridines.
Figure 3: Scope of pyridin-2(1H)-ones and acetophenones.
Scheme 26: CuO NPS-promoted A3 coupling reaction.
Scheme 27: Cu(II)-catalyzed C–N bond formation reaction.
Scheme 28: Mechanism involving Chan–Lam/Ullmann coupling.
Scheme 29: Synthesis of formyl-substituted imidazo[1,2-a]pyridines.
Scheme 30: A tandem sp3 C–H amination reaction.
Scheme 31: Probable mechanistic approach.
Scheme 32: Dual catalytic system for imidazo[1,2-a]pyridines.
Scheme 33: Tentative mechanism.
Scheme 34: CuO/CuAl2O4/ᴅ-glucose-promoted 3-CCR.
Scheme 35: A tandem CuOx/OMS-2-based synthetic strategy.
Figure 4: Biomimetic catalytic oxidation in the presence of electron-transfer mediators (ETMs).
Scheme 36: Control experiment.
Scheme 37: Copper-catalyzed C(sp3)–H aminatin reaction.
Scheme 38: Reaction of secondary amines.
Scheme 39: Probable mechanistic pathway.
Scheme 40: Coupling reaction of α-azidoketones.
Scheme 41: Probable pathway.
Scheme 42: Probable mechanism with free energy calculations.
Scheme 43: MCR for cyanated IP synthesis.
Scheme 44: Substrate scope for the reaction.
Scheme 45: Reaction mechanism.
Scheme 46: Probable mechanistic pathway for Cu/ZnAl2O4-catalyzed reaction.
Scheme 47: Copper-catalyzed double oxidative C–H amination reaction.
Scheme 48: Application towards different coupling reactions.
Scheme 49: Reaction mechanism.
Scheme 50: Condensation–cyclization approach for the synthesis of 1,3-diarylated imidazo[1,5-a]pyridines.
Scheme 51: Optimized reaction conditions.
Scheme 52: One-pot 2-CR.
Scheme 53: One-pot 3-CR without the isolation of chalcone.
Scheme 54: Copper–Pybox-catalyzed cyclization reaction.
Scheme 55: Mechanistic pathway catalyzed by Cu–Pybox complex.
Scheme 56: Cu(II)-promoted C(sp3)-H amination reaction.
Scheme 57: Wider substrate applicability for the reaction.
Scheme 58: Plausible reaction mechanism.
Scheme 59: CuI assisted C–N cross-coupling reaction.
Scheme 60: Probable reaction mechanism involving sp3 C–H amination.
Scheme 61: One-pot MCR-catalyzed by CoFe2O4/CNT-Cu.
Scheme 62: Mechanistic pathway.
Scheme 63: Synthetic scheme for 3-nitroimidazo[1,2-a]pyridines.
Scheme 64: Plausible mechanism for CuBr-catalyzed reaction.
Scheme 65: Regioselective synthesis of halo-substituted imidazo[1,2-a]pyridines.
Scheme 66: Synthesis of 2-phenylimidazo[1,2-a]pyridines.
Scheme 67: Synthesis of diarylated compounds.
Scheme 68: CuBr2-mediated one-pot two-component oxidative coupling reaction.
Scheme 69: Decarboxylative cyclization route to synthesize 1,3-diarylimidazo[1,5-a]pyridines.
Scheme 70: Mechanistic pathway.
Scheme 71: C–H functionalization reaction of enamines to produce diversified heterocycles.
Scheme 72: A plausible mechanism.
Scheme 73: CuI-promoted aerobic oxidative cyclization reaction of ketoxime acetates and pyridines.
Scheme 74: CuI-catalyzed pathway for the formation of imidazo[1,2-a]pyridine.
Scheme 75: Mechanistic pathway.
Scheme 76: Mechanistic rationale for the synthesis of products.
Scheme 77: Copper-catalyzed synthesis of vinyloxy-IP.
Scheme 78: Regioselective product formation with propiolates.
Scheme 79: Proposed mechanism for vinyloxy-IP formation.
Scheme 80: Regioselective synthesis of 3-hetero-substituted imidazo[1,2-a]pyridines with different reaction su...
Scheme 81: Mechanistic pathway.
Scheme 82: CuI-mediated synthesis of 3-formylimidazo[1,2-a]pyridines.
Scheme 83: Radical pathway for 3-formylated IP synthesis.
Scheme 84: Pd-catalyzed urea-cyclization reaction for IPs.
Scheme 85: Pd-catalyzed one-pot-tandem amination and intramolecular amidation reaction.
Figure 5: Scope of aniline nucleophiles.
Scheme 86: Pd–Cu-catalyzed Sonogashira coupling reaction.
Scheme 87: One-pot amide coupling reaction for the synthesis of imidazo[4,5-b]pyridines.
Scheme 88: Urea cyclization reaction for the synthesis of two series of pyridines.
Scheme 89: Amidation reaction for the synthesis of imidazo[4,5-b]pyridines.
Figure 6: Amide scope.
Scheme 90: Pd NPs-catalyzed 3-component reaction for the synthesis of 2,3-diarylated IPs.
Scheme 91: Plausible mechanistic pathway for Pd NPs-catalyzed MCR.
Scheme 92: Synthesis of chromenoannulated imidazo[1,2-a]pyridines.
Scheme 93: Mechanism for the synthesis of chromeno-annulated IPs.
Scheme 94: Zinc oxide NRs-catalyzed synthesis of imidazo[1,2-a]azines/diazines.
Scheme 95: Zinc oxide-catalyzed isocyanide based GBB reaction.
Scheme 96: Reaction pathway for ZnO-catalyzed GBB reaction.
Scheme 97: Mechanistic pathway.
Scheme 98: ZnO NRs-catalyzed MCR for the synthesis of imidazo[1,2-a]azines.
Scheme 99: Ugi type GBB three-component reaction.
Scheme 100: Magnetic NPs-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 101: Regioselective synthesis of 2-alkoxyimidazo[1,2-a]pyridines catalyzed by Fe-SBA-15.
Scheme 102: Plausible mechanistic pathway for the synthesis of 2-alkoxyimidazopyridine.
Scheme 103: Iron-catalyzed synthetic approach.
Scheme 104: Iron-catalyzed aminooxygenation reaction.
Scheme 105: Mechanistic pathway.
Scheme 106: Rh(III)-catalyzed double C–H activation of 2-substituted imidazoles and alkynes.
Scheme 107: Plausible reaction mechanism.
Scheme 108: Rh(III)-catalyzed non-aromatic C(sp2)–H bond activation–functionalization for the synthesis of imid...
Scheme 109: Reactivity and selectivity of different substrates.
Scheme 110: Rh-catalyzed direct C–H alkynylation by Li et al.
Scheme 111: Suggested radical mechanism.
Scheme 112: Scandium(III)triflate-catalyzed one-pot reaction and its mechanism for the synthesis of benzimidazo...
Scheme 113: RuCl3-assisted Ugi-type Groebke–Blackburn condensation reaction.
Scheme 114: C-3 aroylation via Ru-catalyzed two-component reaction.
Scheme 115: Regioselective synthetic mechanism.
Scheme 116: La(III)-catalyzed one-pot GBB reaction.
Scheme 117: Mechanistic approach for the synthesis of imidazo[1,2-a]pyridines.
Scheme 118: Synthesis of imidazo[1,2-a]pyridine using LaMnO3 NPs under neat conditions.
Scheme 119: Mechanistic approach.
Scheme 120: One-pot 3-CR for regioselective synthesis of 2-alkoxy-3-arylimidazo[1,2-a]pyridines.
Scheme 121: Formation of two possible products under optimization of the catalysts.
Scheme 122: Mechanistic strategy for NiFe2O4-catalyzed reaction.
Scheme 123: Two-component reaction for synthesizing imidazodipyridiniums.
Scheme 124: Mechanistic scheme for the synthesis of imidazodipyridiniums.
Scheme 125: CuI-catalyzed arylation of imidazo[1,2-a]pyridines.
Scheme 126: Mechanism for arylation reaction.
Scheme 127: Cupric acetate-catalyzed double carbonylation approach.
Scheme 128: Radical mechanism for double carbonylation of IP.
Scheme 129: C–S bond formation reaction catalyzed by cupric acetate.
Scheme 130: Cupric acetate-catalyzed C-3 formylation approach.
Scheme 131: Control experiments for signifying the role of DMSO and oxygen.
Scheme 132: Mechanism pathway.
Scheme 133: Copper bromide-catalyzed CDC reaction.
Scheme 134: Extension of the substrate scope.
Scheme 135: Plausible radical pathway.
Scheme 136: Transannulation reaction for the synthesis of imidazo[1,5-a]pyridines.
Scheme 137: Plausible reaction pathway for denitrogenative transannulation.
Scheme 138: Cupric acetate-catalyzed C-3 carbonylation reaction.
Scheme 139: Plausible mechanism for regioselective C-3 carbonylation.
Scheme 140: Alkynylation reaction at C-2 of 3H-imidazo[4,5-b]pyridines.
Scheme 141: Two-way mechanism for C-2 alkynylation of 3H-imidazo[4,5-b]pyridines.
Scheme 142: Palladium-catalyzed SCCR approach.
Scheme 143: Palladium-catalyzed Suzuki coupling reaction.
Scheme 144: Reaction mechanism.
Scheme 145: A phosphine free palladium-catalyzed synthesis of C-3 arylated imidazopyridines.
Scheme 146: Palladium-mediated Buchwald–Hartwig cross-coupling reaction.
Figure 7: Structure of the ligands optimized.
Scheme 147: Palladium acetate-catalyzed direct arylation of imidazo[1,2-a]pyridines.
Scheme 148: Palladium acetate-catalyzed mechanistic pathway.
Scheme 149: Palladium acetate-catalyzed regioselective arylation reported by Liu and Zhan.
Scheme 150: Mechanism for selective C-3 arylation of IP.
Scheme 151: Pd(II)-catalyzed alkenylation reaction with styrenes.
Scheme 152: Pd(II)-catalyzed alkenylation reaction with acrylates.
Scheme 153: A two way mechanism.
Scheme 154: Double C–H activation reaction catalyzed by Pd(OAc)2.
Scheme 155: Probable mechanism.
Scheme 156: Palladium-catalyzed decarboxylative coupling.
Scheme 157: Mechanistic cycle for decarboxylative arylation reaction.
Scheme 158: Ligand-free approach for arylation of imidazo[1,2-a]pyridine-3-carboxylic acids.
Scheme 159: Mechanism for ligandless arylation reaction.
Scheme 160: NHC-Pd(II) complex assisted arylation reaction.
Scheme 161: C-3 arylation of imidazo[1,2-a]pyridines with aryl bromides catalyzed by Pd(OAc)2.
Scheme 162: Pd(II)-catalyzed C-3 arylations with aryl tosylates and mesylates.
Scheme 163: CDC reaction for the synthesis of imidazo[1,2-a]pyridines.
Scheme 164: Plausible reaction mechanism for Pd(OAc)2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 165: Pd-catalyzed C–H amination reaction.
Scheme 166: Mechanism for C–H amination reaction.
Scheme 167: One-pot synthesis for 3,6-di- or 2,3,6-tri(hetero)arylimidazo[1,2-a]pyridines.
Scheme 168: C–H/C–H cross-coupling reaction of IPs and azoles catalyzed by Pd(II).
Scheme 169: Mechanistic cycle.
Scheme 170: Rh-catalyzed C–H arylation reaction.
Scheme 171: Mechanistic pathway for C–H arylation of imidazo[1,2-a]pyridine.
Scheme 172: Rh(III)-catalyzed double C–H activation of 2-phenylimidazo[1,2-a]pyridines and alkynes.
Scheme 173: Rh(III)-catalyzed mechanistic pathway.
Scheme 174: Rh(III)-mediated oxidative coupling reaction.
Scheme 175: Reactions showing functionalization of the product obtained by the group of Kotla.
Scheme 176: Mechanism for Rh(III)-catalyzed oxidative coupling reaction.
Scheme 177: Rh(III)-catalyzed C–H activation reaction.
Scheme 178: Mechanistic cycle.
Scheme 179: Annulation reactions of 2-arylimidazo[1,2-a]pyridines and alkynes.
Scheme 180: Two-way reaction mechanism for annulations reaction.
Scheme 181: [RuCl2(p-cymene)]2-catalyzed C–C bond formation reaction.
Scheme 182: Reported reaction mechanism.
Scheme 183: Fe(III) catalyzed C-3 formylation approach.
Scheme 184: SET mechanism-catalyzed by Fe(III).
Scheme 185: Ni(dpp)Cl2-catalyzed KTC coupling.
Scheme 186: Pd-catalyzed SM coupling.
Scheme 187: Vanadium-catalyzed coupling of IP and NMO.
Scheme 188: Mechanistic cycle.
Scheme 189: Selective C3/C5–H bond functionalizations by mono and bimetallic systems.
Scheme 190: rGO-Ni@Pd-catalyzed C–H bond arylation of imidazo[1,2-a]pyridine.
Scheme 191: Mechanistic pathway for heterogeneously catalyzed arylation reaction.
Scheme 192: Zinc triflate-catalyzed coupling reaction of substituted propargyl alcohols.